27Sep 2022
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. Although the GMT of neutralising antibodies in the BNT162b2 group was significantly reduced six months after the second dose, the SCR remained at 58.8%. BNT162b2-elicited sera neutralised SARS-CoV-2 variants of concern. BNT162b2 vaccination induced a robust immune response with acceptable tolerability in Han Chinese adults. However, the follow-up duration was relatively short, and COVID-19 rates were not assessed. Safety data collection continues until 12 months after the second dose.

  • #family health

Like

Save

Share